• 2634 Citations
  • 23 h-Index
1994 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Jae Hong Seo is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 6 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


Research Output

A pilot study on intermittent every other days of 5-dose Filgrastim compared with single Pegfilgrastim in breast Cancer patients receiving adjuvant Docetaxel, doxorubicin, and cyclophosphamide (TAC) chemotherapy

Sohn, B. S., Jeong, J. H., Ahn, J. H., Jung, K. H., Kim, J. E., Sohn, J. H., Koh, S. J., Seo, J. H., Lee, K. S. & Kim, S. B., 2020 Jun 1, In : Investigational New Drugs. 38, 3, p. 866-873 8 p.

Research output: Contribution to journalArticle

  • Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients with Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial

    Shao, Z., Pang, D., Yang, H., Li, W., Wang, S., Cui, S., Liao, N., Wang, Y., Wang, C., Chang, Y. C., Wang, H., Kang, S. Y., Seo, J. H., Shen, K., Laohawiriyakamol, S., Jiang, Z., Li, J., Zhou, J., Althaus, B., Mao, Y. & 1 others, Eng-Wong, J., 2020 Mar, In : JAMA Oncology. 6, 3

    Research output: Contribution to journalArticle

  • 5 Citations (Scopus)

    Inflammatory markers as prognostic indicators in pancreatic cancer patients who underwent gemcitabine-based palliative chemotherapy

    Kim, H. J., Lee, S. Y., Kim, D. S., Kang, E. J., Kim, J. S., Choi, Y. J., Oh, S. C., Seo, J. H. & Kim, J. S., 2020, In : Korean Journal of Internal Medicine. 35, 1, p. 172-184 13 p.

    Research output: Contribution to journalArticle

    Open Access
  • 2 Citations (Scopus)

    AGTR1 aptamer-anticancer drug complex for cancer cell chemotherapy

    Seo, J. H., 2019 Feb 5, Patent No. 10195285

    Research output: Patent

  • C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition

    Cho, T. M., Kim, J. Y., Kim, Y. J., Sung, D., Oh, E., Jang, S., Farrand, L., Hoang, V. H., Nguyen, C. T., Ann, J., Lee, J. & Seo, J. H., 2019 Apr 10, In : Cancer Letters. 447, p. 141-153 13 p.

    Research output: Contribution to journalArticle

  • 7 Citations (Scopus)